ZIOPHARM (ZIOP) Reports Q3 Loss Doubles
- Top 10 News for 12/02 - 12/06: Facebook Snubbed Again; Bitcoin Mania!; New Deal for Apple?
- U.S. Adds Jobs at Higher Clip in November, Unemployment Rate Falls to 7%
- Bitcoin Crashes 21%
- Unusual 11 Mid-Day Movers 12/06: (MBLX) (VIFL) (BLDP) Higher; (RALY) (ULTA) (SEAC) Lower
- Sears Holdings (SHLD) Files to Spin-Off Lands' End Unit
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) reports Q3 loss of $0.26, versus ($0.13) reported for the same period a year ago.
You May Also Be Interested In
- ZIOPHARM Oncology (ZIOP) Receives NIH RAC Approval for Ad-RTS-IL-12 Phase 1
- ZIOPHARM Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval for Phase 1 Study of Ad-RTS-IL-12 in Subjects With Recurrent or Progressive Glioblastoma
- Big Lots, Inc. (BIG) Misses Q3 EPS by 14c; Plans to Exit Canadian Operations
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!